Previous close | 153.78 |
Open | 158.00 |
Bid | 0.00 x 0 |
Ask | 0.00 x 0 |
Day's range | 157.89 - 158.43 |
52-week range | 118.16 - 159.84 |
Volume | |
Avg. volume | 3,246 |
Market cap | 245.605B |
Beta (5Y monthly) | 0.16 |
PE ratio (TTM) | 39.22 |
EPS (TTM) | N/A |
Earnings date | N/A |
Forward dividend & yield | 2.86 (1.86%) |
Ex-dividend date | 22 Feb 2024 |
1y target est | N/A |
WILMINGTON, Del., June 02, 2024--Positive results from the LAURA Phase III trial showed AstraZeneca’s TAGRISSO® (osimertinib) demonstrated a statistically significant and highly clinically meaningful improvement in progression-free survival (PFS) for patients with unresectable, Stage III epidermal growth factor receptor-mutated (EGFRm) non-small cell lung cancer (NSCLC) whose tumors have exon 19 deletions or exon 21 (L858R) mutations, after chemoradiotherapy (CRT) compared to placebo after CRT.
WILMINGTON, Del., June 02, 2024--Positive results from the ADRIATIC Phase III trial showed AstraZeneca’s IMFINZI® (durvalumab) demonstrated statistically significant and clinically meaningful improvements in the dual primary endpoints of overall survival (OS) and progression-free survival (PFS) compared to placebo for patients with limited-stage small cell lung cancer (LS-SCLC) who had not progressed following standard-of-care concurrent chemoradiotherapy (cCRT).
WILMINGTON, Del., June 02, 2024--Detailed positive results from the DESTINY-Breast06 Phase III trial showed that ENHERTU® (fam-trastuzumab deruxtecan-nxki) demonstrated a statistically significant and clinically meaningful improvement in progression-free survival (PFS) compared to standard-of-care chemotherapy in patients with HR-positive, HER2-low (IHC 1+ or 2+/ISH-) metastatic breast cancer and the overall trial population (patients with HR-positive, HER2-low and HER2-ultralow [defined as IHC